https://www.kentuckyhealthwire.com/article/907800388-rta-outdoor-living-launches-health-haven-youtube-special-on-backyard-design-and-health Kentucky Health Wire en PressRelease 2026-04-24T17:10:00+00:00 RTA Outdoor Living Launches 'Health Haven' YouTube Special on Backyard Design and Health https://pressranger.s3.us-west-1.amazonaws.com/3235413/RTA-Health-Haven.jpg https://www.kentuckyhealthwire.com/article/907798892-metabo-drops-2026-launch-tasteless-drop-effective-weight-loss-turns-any-coffee-into-boosted-metabolism-explained-fat-burning-supplement-metabodrops Kentucky Health Wire en PressRelease 2026-04-24T16:05:46+00:00 Metabo Drops 2026 | Launch "Tasteless Drop Effective Weight Loss Turns Any Coffee Into Boosted Metabolism Explained Fat Burning Supplement MetaboDrops https://ml-eu.globenewswire.com/Resource/Download/3bf2deb4-4049-4eb5-94c2-48515480ddd1/untitled-design.jpg https://www.kentuckyhealthwire.com/article/907764139-kfsh-scales-genomic-medicine-from-research-to-clinical-decision-making Kentucky Health Wire en PressRelease 2026-04-24T15:23:15+00:00 KFSH Scales Genomic Medicine from Research to Clinical Decision-Making https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png https://www.kentuckyhealthwire.com/article/907759706-indivior-presents-new-real-world-data-at-asam-2026-annual-conference-supporting-remission-as-a-treatment-outcome-and-reinforcing-the-clinical Kentucky Health Wire en PressRelease 2026-04-24T15:00:00+00:00 Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder https://ml-eu.globenewswire.com/media/42de3285-90ea-4020-a3ad-25f71026b41a/small/indivior-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907763997-dna-day-2026-genelife-advances-geneai-forecast-with-15-predictive-models-and-enhanced-lifestyle-integration Kentucky Health Wire en PressRelease 2026-04-24T14:43:07+00:00 DNA DAY™ 2026: GeneLife Advances GeneAI Forecast with 15 Predictive Models and Enhanced Lifestyle Integration https://ml.globenewswire.com/media/57b381e4-7649-49a9-bf54-e247c5a8cf1f/small/adam-innovations-horizontal-png.png https://www.kentuckyhealthwire.com/article/907759597-medicana-health-group-launches-hpv-vaccination-and-cervical-cancer-awareness-campaign-advancing-prevention-through-regular-check-ups Kentucky Health Wire en PressRelease 2026-04-24T14:37:44+00:00 Medicana Health Group Launches HPV Vaccination and Cervical Cancer Awareness Campaign, Advancing Prevention Through Regular Check-Ups https://ml-eu.globenewswire.com/media/06c0ab7c-b420-4596-bede-a390553593aa/medium/medicana-atakoy-hospital-in-istanbul.png https://www.kentuckyhealthwire.com/article/907761369-a-d-a-m-innovations-unveils-genelock-the-world-s-first-genetic-data-protection-platform Kentucky Health Wire en PressRelease 2026-04-24T14:19:03+00:00 A.D.A.M. Innovations Unveils GeneLock™: The World’s First Genetic Data Protection Platform https://ml.globenewswire.com/media/57b381e4-7649-49a9-bf54-e247c5a8cf1f/small/adam-innovations-horizontal-png.png https://www.kentuckyhealthwire.com/article/907759565-the-genius-song-the-brain-song-official-2026-7-second-brain-trick-genius-brainwave-music-to-improve-focus-and-memory-by-genius-wave Kentucky Health Wire en PressRelease 2026-04-24T14:17:10+00:00 The Genius Song & The Brain Song Official 2026: 7-Second Brain Trick’  Genius Brainwave Music to Improve Focus and memory By Genius wave? https://ml-eu.globenewswire.com/Resource/Download/e3c386da-82aa-41df-a99a-5d137fea950c/248c38ea-054b-4243-9dd0-8047be50f80a.png https://www.kentuckyhealthwire.com/article/907761517-actg-launches-landmark-study-evaluating-treatments-for-depressive-disorders-with-or-without-mild-neurocognitive-disorder-among-people-living-with-hiv Kentucky Health Wire en PressRelease 2026-04-24T14:05:48+00:00 ACTG Launches Landmark Study Evaluating Treatments for Depressive Disorders with or without Mild Neurocognitive Disorder among People Living with HIV https://ml.globenewswire.com/media/1e94313a-1d33-49e8-bd5e-fd0c911661c9/small/image1-png.png https://www.kentuckyhealthwire.com/article/907761456-new-lung-preservation-studies-showcase-key-insights-of-optimizing-temperature-and-airway-pressure-control Kentucky Health Wire en PressRelease 2026-04-24T13:43:35+00:00 New Lung Preservation Studies Showcase Key Insights of Optimizing Temperature and Airway Pressure Control https://ml.globenewswire.com/media/5b56fec1-dc1d-480e-8a0b-aa723d7e7cf9/small/paragonix-getinge-bluecenter-png.png https://www.kentuckyhealthwire.com/article/907760154-acentra-health-chief-ai-officer-sean-harrison-named-to-nvtc-ai50 Kentucky Health Wire en PressRelease 2026-04-24T13:33:00+00:00 Acentra Health Chief AI Officer Sean Harrison Named to NVTC AI50 https://ml.globenewswire.com/media/d6577e18-c840-416c-9ce5-fce049b2b0b8/medium/acentra-health-chief-ai-officer-sean-harrison-2026-nvtc-ai50.png https://www.kentuckyhealthwire.com/article/907736721-alvotech-to-report-financial-results-for-the-first-quarter-of-2026 Kentucky Health Wire en PressRelease 2026-04-24T12:30:00+00:00 Alvotech to Report Financial Results for the First Quarter of 2026 https://ml-eu.globenewswire.com/media/17a8091d-68a6-47c1-968e-fcced99f1d44/small/alvotech-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907737194-jushi-holdings-inc-announces-proposed-continuance-from-british-columbia-to-nevada Kentucky Health Wire en PressRelease 2026-04-24T12:30:00+00:00 Jushi Holdings Inc. Announces Proposed Continuance from British Columbia to Nevada https://ml.globenewswire.com/media/e65f15fd-322c-4847-83c5-ceafe27f97d5/small/jushi-png.png https://www.kentuckyhealthwire.com/article/907741044-gain-therapeutics-announces-oral-presentation-at-3rd-international-gba1-meeting-2026 Kentucky Health Wire en PressRelease 2026-04-24T12:30:00+00:00 Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026 https://ml.globenewswire.com/media/b08fa984-9f20-4aa1-a174-b9f6165d50fa/small/gainlogo-png.png https://www.kentuckyhealthwire.com/article/907736804-aligos-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Kentucky Health Wire en PressRelease 2026-04-24T12:00:00+00:00 Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/03ffbe89-c47f-4f83-b51f-f13a572e2cd1/small/aligos-png.png https://www.kentuckyhealthwire.com/article/907736818-media-advisory-ontario-health-coalition-large-cross-province-protests-this-saturday-ford-gov-t-pushing-our-hospitals-into-deficit-cuts-while-paying Kentucky Health Wire en PressRelease 2026-04-24T12:00:00+00:00 Media Advisory-Ontario Health Coalition/Large cross-province protests this Saturday: Ford gov’t pushing our hospitals into deficit & cuts while paying more to privatize their services https://ml.globenewswire.com/media/fdd00e9f-f066-4244-85e8-d12e6d1b760c/small/screen-shot-2023-09-14-at-1-49-15-pm-png.png https://www.kentuckyhealthwire.com/article/907739284-oncotelic-therapeutics-provides-corporate-update-on-partnership-strategy Kentucky Health Wire en PressRelease 2026-04-24T12:00:00+00:00 Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy https://ml.globenewswire.com/media/b57f4b15-bff1-4da1-872b-ed2b51984ad9/small/logo-png.png https://www.kentuckyhealthwire.com/article/907739927-humacyte-expands-commercial-and-business-development-opportunities-through-realignment-of-ex-u-s-rights-to-symvess Kentucky Health Wire en PressRelease 2026-04-24T12:00:00+00:00 Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess® https://ml.globenewswire.com/media/e81aff26-ead8-404d-aebb-159b45c3e7b1/small/huma-logo-png.png https://www.kentuckyhealthwire.com/article/907740707-kyowa-kirin-and-kura-oncology-initiate-japanese-phase-2-registration-directed-trial-of-ziftomenib-in-r-r-npm1-m-aml Kentucky Health Wire en PressRelease 2026-04-24T12:00:00+00:00 Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML https://ml.globenewswire.com/media/OTAwNGNlMDQtMzYzYy00OGU0LWFmMDEtNGJlZjYxMmFkYTBiLTUwMDE1MDY0OC0yMDI2LTA0LTI0LWVu/tiny/Kyowa-Kirin.png https://www.kentuckyhealthwire.com/article/907739939-30-years-of-smiles-st-augustine-s-premier-cosmetic-dentist-marks-a-career-built-on-artistry Kentucky Health Wire en PressRelease 2026-04-24T11:15:00+00:00 30 Years of Smiles: St. Augustine’s Premier Cosmetic Dentist Marks a Career Built on Artistry https://ml.globenewswire.com/media/4f184569-4d95-4d3d-931d-5e5f91a99b7c/medium/dr-atosa-khan-and-her-team-in-st-augustine-dental-office.jpg https://www.kentuckyhealthwire.com/article/907739950-free-carotenoid-eye-screenings-offered-to-seacoast-residents-near-portsmouth-nh Kentucky Health Wire en PressRelease 2026-04-24T11:15:00+00:00 Free Carotenoid Eye Screenings Offered to Seacoast Residents Near Portsmouth, NH https://ml.globenewswire.com/media/d978536b-c1ca-4073-80a0-49c16a604507/medium/modern-vision-center-near-portsmouth-nh-eye-exams-and-optica.jpg https://www.kentuckyhealthwire.com/article/907740309-dogecoin-cash-inc-highlights-telehealth-platform-strategy-following-federal-actions-relating-to-marijuana-reclassification Kentucky Health Wire en PressRelease 2026-04-24T11:15:00+00:00 Dogecoin Cash, Inc. Highlights Telehealth Platform Strategy Following Federal Actions Relating to Marijuana Reclassification https://ml.globenewswire.com/media/59f902b1-29a7-4b48-a71a-96f3cf2ed92e/small/dc-cash-header-new-jpg.jpg https://www.kentuckyhealthwire.com/article/907737483-treace-to-report-first-quarter-2026-financial-results-on-may-8-2026 Kentucky Health Wire en PressRelease 2026-04-24T11:05:00+00:00 Treace to Report First Quarter 2026 Financial Results on May 8, 2026 https://ml.globenewswire.com/media/e6af4ccc-19b1-4fe0-948f-436f2b9d2ea5/small/treace-color-jpg.jpg https://www.kentuckyhealthwire.com/article/907739736-senseonics-announces-european-launch-of-eversense-365-the-world-s-first-and-only-one-year-cgm-system Kentucky Health Wire en PressRelease 2026-04-24T11:00:00+00:00 Senseonics Announces European Launch of Eversense® 365, The World’s First and Only One Year CGM System https://ml.globenewswire.com/media/7f64f449-dd5d-4bd1-9504-82adb3846669/small/logo-png.png https://www.kentuckyhealthwire.com/article/907741286-syndax-to-announce-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-april-30-2026 Kentucky Health Wire en PressRelease 2026-04-24T11:00:00+00:00 Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026 https://ml.globenewswire.com/media/399a65b5-bd4f-4ba5-980b-f4d0af9ae6a0/small/syndax-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907740603-ani-pharmaceuticals-to-discuss-first-quarter-2026-financial-results-on-may-8-2026-at-8-00-a-m-et Kentucky Health Wire en PressRelease 2026-04-24T10:50:00+00:00 ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET https://ml.globenewswire.com/media/24d1d851-9075-4d6e-b22c-0c23a5ef0b36/small/ani-logo-png.png https://www.kentuckyhealthwire.com/article/907715752-press-release-sanofi-s-cenrifki-tolebrutinib-recommended-for-eu-approval-by-the-chmp-to-treat-secondary-progressive-multiple-sclerosis-without Kentucky Health Wire en PressRelease 2026-04-24T10:09:31+00:00 Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907715819-communiqu-de-presse-cenrifki-de-sanofi-tolebrutinib-recommand-par-le-comit-des-m-dicaments-usage-humain-cmuh-pour-tre-approuv-par-l-ue Kentucky Health Wire en PressRelease 2026-04-24T10:09:31+00:00 Communiqué de presse : Cenrifki de Sanofi (tolebrutinib) recommandé par le Comité des médicaments à usage humain (CMUH) pour être approuvé par l’UE pour le traitement de la sclérose en plaques secondairement progressive sans poussées https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907694179-amphista-therapeutics-announces-presentation-of-new-preclinical-data-from-its-smarca2-and-tead-targeted-glue-degrader-programs-at-aacr-2026-and Kentucky Health Wire en PressRelease 2026-04-24T08:00:27+00:00 Amphista Therapeutics announces presentation of new preclinical data from its SMARCA2 and TEAD Targeted Glue™ degrader programs at AACR 2026, and publication of the first data on its TEAD program https://ml-eu.globenewswire.com/media/d3d2174f-591e-4e13-9a89-363dcbfe5c68/small/amphista-horiz-logo-rgb-1500px-png.png https://www.kentuckyhealthwire.com/article/907693813-levicept-to-present-data-from-phase-ii-study-of-levi-04-at-oarsi-2026-world-congress-on-osteoarthritis Kentucky Health Wire en PressRelease 2026-04-24T08:00:00+00:00 Levicept to Present Data from Phase II study of LEVI-04 at OARSI 2026 World Congress on Osteoarthritis https://ml-eu.globenewswire.com/media/44086146-ae7c-40ad-9e1d-326ca3bfbf7e/small/levicept-logo-png.png https://www.kentuckyhealthwire.com/article/907694096-geneva-college-of-longevity-science-launches-the-world-s-first-phd-in-longevity-sciences Kentucky Health Wire en PressRelease 2026-04-24T07:40:52+00:00 Geneva College of Longevity Science Launches the World’s First PhD in Longevity Sciences https://ml-eu.globenewswire.com/media/OWQzNGMzY2EtZDhmMi00NGJiLTgzY2MtMmNkZjAwZTJkZjMyLTEzMTkzMzAtMjAyNi0wNC0yNC1lbg==/tiny/GCLS.png https://www.kentuckyhealthwire.com/article/907672922-clinuvel-receives-final-ema-scientific-advice-for-pivotal-phase-iii-vitiligo-study Kentucky Health Wire en PressRelease 2026-04-24T05:47:18+00:00 CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study https://ml.globenewswire.com/media/e44ebc14-276f-4e7b-9f19-76924f349ecf/small/navy-cuv-logo-rgb-1200x628px-png.png https://www.kentuckyhealthwire.com/article/907671711-novartis-malaria-treatment-coartem-baby-receives-who-prequalification-paving-way-for-greater-access-for-newborns-and-young-infants Kentucky Health Wire en PressRelease 2026-04-24T05:15:00+00:00 Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants https://ml-eu.globenewswire.com/media/f0161a05-9638-4da5-a4af-f9cdb28f0304/small/logo-warm-black-rgb-jpg.jpg https://www.kentuckyhealthwire.com/article/907651064-fda-approves-first-ever-gene-therapy-for-treatment-of-genetic-hearing-loss-under-national-priority-voucher-program Kentucky Health Wire en PressRelease 2026-04-24T02:04:21+00:00 FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program https://ml.globenewswire.com/media/ZDc3Yjg1MzAtMzMxYi00M2Q4LTg1ZDYtYWM5NmVjN2E5OGIxLTUwMDE1NDE1NC0yMDI2LTA0LTI0LWVu/tiny/FDA.png https://www.kentuckyhealthwire.com/article/907606651-agomab-reports-full-year-2025-financial-results-and-confirms-2026-outlook Kentucky Health Wire en PressRelease 2026-04-23T22:14:17+00:00 Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook https://ml-eu.globenewswire.com/media/7f797bcb-5d5d-4fb6-a862-b5c861b83e54/small/agomab-logo-png.png https://www.kentuckyhealthwire.com/article/907608934-kane-biotech-announces-fourth-quarter-and-full-year-2025-financial-results Kentucky Health Wire en PressRelease 2026-04-23T22:00:00+00:00 Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results https://ml.globenewswire.com/media/a2ad1d52-1d5a-425c-93de-45cc52c3784b/small/kane-logo-cropped-transbg-png.png https://www.kentuckyhealthwire.com/article/907609136-denta-biome-under-investigation-adem-naturals-chewable-dental-tablets-for-oral-health-care-support Kentucky Health Wire en PressRelease 2026-04-23T21:55:49+00:00 Denta Biome Under Investigation: Adem Naturals Chewable Dental Tablets for Oral Health Care Support https://zingfast.com/wp-content/uploads/2026/04/Denta-Biome-1.jpg https://www.kentuckyhealthwire.com/article/907608901-skinnyrx-glp-1-claims-evaluated-review-semaglutide-tirzepatide-weight-loss-medication-options-with-clinician-guided-care Kentucky Health Wire en PressRelease 2026-04-23T21:14:21+00:00 SkinnyRx GLP-1 Claims Evaluated: Review Semaglutide & Tirzepatide Weight Loss Medication Options with Clinician-Guided Care https://zingfast.com/wp-content/uploads/2026/04/SkinnyRx-GLP-1.jpg https://www.kentuckyhealthwire.com/article/907608533-vaxart-appoints-james-breitmeyer-m-d-ph-d-to-board-of-directors Kentucky Health Wire en PressRelease 2026-04-23T20:30:00+00:00 Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors https://ml.globenewswire.com/media/aedaf06c-26f8-482c-ac72-39774eab2c35/small/vxrt-logo-jpg.png https://www.kentuckyhealthwire.com/article/907606817-chemed-reports-first-quarter-2026-results Kentucky Health Wire en PressRelease 2026-04-23T20:15:00+00:00 Chemed Reports First-Quarter 2026 Results https://ml.globenewswire.com/media/1ab951c0-8d76-40e0-bc65-ebeaa1731e66/small/chemed-corp-logo-600x400-jpg.jpg https://www.kentuckyhealthwire.com/article/907587196-avita-medical-to-announce-first-quarter-2026-financial-results Kentucky Health Wire en PressRelease 2026-04-23T20:10:00+00:00 AVITA Medical to Announce First Quarter 2026 Financial Results https://ml.globenewswire.com/media/53ad8139-952a-4470-9ede-2f3bf0521f16/small/avita-png.png https://www.kentuckyhealthwire.com/article/907586585-dyne-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Kentucky Health Wire en PressRelease 2026-04-23T20:05:00+00:00 Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg https://www.kentuckyhealthwire.com/article/907587189-outlook-therapeutics-announces-closing-of-5-0-million-registered-direct-offering Kentucky Health Wire en PressRelease 2026-04-23T20:05:00+00:00 Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering https://ml.globenewswire.com/media/cbff3302-f8d2-466a-beff-8c33252f9c70/small/otlk-png.png https://www.kentuckyhealthwire.com/article/907587246-trevi-therapeutics-to-participate-in-upcoming-may-events Kentucky Health Wire en PressRelease 2026-04-23T20:05:00+00:00 Trevi Therapeutics to Participate in Upcoming May Events https://ml.globenewswire.com/media/b97e9d57-6e8e-4570-87da-ea38c273f7c8/small/trevi-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907587485-heartflow-to-report-first-quarter-2026-financial-results-on-may-14-2026 Kentucky Health Wire en PressRelease 2026-04-23T20:05:00+00:00 Heartflow to Report First Quarter 2026 Financial Results on May 14, 2026 https://ml.globenewswire.com/media/c6be111e-2f8e-4ac8-8fa8-310dbcbd6e15/small/25-1113-cmyk-hf-logo-positive-png.png https://www.kentuckyhealthwire.com/article/907587550-leonabio-to-host-virtual-key-opinion-leader-event-highlighting-potential-of-lasofoxifene-in-treatment-resistant-er-her2-esr1-mutated-metastatic Kentucky Health Wire en PressRelease 2026-04-23T20:05:00+00:00 LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer https://ml.globenewswire.com/media/84ac024a-139b-463f-a43f-ed787a66c0fd/small/image1-jpg.jpg https://www.kentuckyhealthwire.com/article/907587597-cytek-biosciences-to-report-first-quarter-2026-financial-results-on-may-7-2026 Kentucky Health Wire en PressRelease 2026-04-23T20:05:00+00:00 Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 https://ml.globenewswire.com/media/5a33b17c-e545-48d8-b797-832cf8e4372c/small/cytek-logo-color-jpg.jpg https://www.kentuckyhealthwire.com/article/907588857-itonic-holdings-ltd-granted-an-extension-of-additional-180-day-by-nasdaq-to-regain-compliance-with-minimum-bid-price-rule Kentucky Health Wire en PressRelease 2026-04-23T20:05:00+00:00 iTonic Holdings Ltd Granted An Extension of Additional 180-Day by Nasdaq to Regain Compliance with Minimum Bid Price Rule https://ml.globenewswire.com/media/7785d449-a9e0-4ea1-86eb-ff46d45db4db/small/phetonlogo-jpg.jpg https://www.kentuckyhealthwire.com/article/907586362-kiniksa-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-april-28-2026 Kentucky Health Wire en PressRelease 2026-04-23T20:01:00+00:00 Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026 https://ml-eu.globenewswire.com/media/84055882-69ed-48db-be7d-99cc55be5ff3/small/image1-jpg.jpg https://www.kentuckyhealthwire.com/article/907586974-weight-watchers-schedules-first-quarter-2026-earnings-conference-call Kentucky Health Wire en PressRelease 2026-04-23T20:01:00+00:00 Weight Watchers Schedules First Quarter 2026 Earnings Conference Call https://ml.globenewswire.com/media/f435b439-7f75-4d2f-a6cc-0e4e2ed811ea/small/weightwatchers-wordmark-boldblue-png.png https://www.kentuckyhealthwire.com/article/907587307-tectonic-therapeutic-appoints-jessica-chutter-to-board-of-directors Kentucky Health Wire en PressRelease 2026-04-23T20:01:00+00:00 Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors https://ml.globenewswire.com/media/7c13d2a1-2971-4ab0-a4b5-608923316546/small/tectonic-logo-full-color-png.png https://www.kentuckyhealthwire.com/article/907590339-the-root-brands-earns-national-recognition-for-patent-driven-wellness-innovation-and-science-backed-consumer-products Kentucky Health Wire en PressRelease 2026-04-23T19:53:45+00:00 The ROOT Brands Earns National Recognition for Patent‑Driven Wellness Innovation and Science‑Backed Consumer Products https://ml.globenewswire.com/media/NTRkM2NjZTItMGM5Yy00OWVjLTk0M2MtM2Q1YWI1NzI0NWU4LTUwMDE1MDU0NC0yMDI2LTA0LTIzLWVu/tiny/The-ROOT-Brands.png https://www.kentuckyhealthwire.com/article/907589890-regeneron-announces-agreement-with-u-s-government-to-help-lower-drug-costs-for-american-patients-and-will-provide-innovative-new-gene-therapy-for Kentucky Health Wire en PressRelease 2026-04-23T19:46:16+00:00 Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S. https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907589070-this-alcohol-awareness-month-oxford-treatment-center-raises-red-flag-citing-significant-rise-in-patients-seeking-help-for-alcohol-addiction Kentucky Health Wire en PressRelease 2026-04-23T19:45:00+00:00 This Alcohol Awareness Month, Oxford Treatment Center Raises Red Flag, Citing Significant Rise in Patients Seeking Help for Alcohol Addiction https://ml.globenewswire.com/media/0b3eec6b-83f7-4bfa-8d29-d07dbb759e65/small/oxford-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907589816-cook-county-health-recognizes-60th-anniversary-of-trauma-unit Kentucky Health Wire en PressRelease 2026-04-23T19:38:53+00:00 Cook County Health Recognizes 60th Anniversary of Trauma Unit https://ml.globenewswire.com/media/NDQ1YjhiYjctOTZhNS00YjAxLWI1ZGQtNjkzN2EzNzY5MmUyLTUwMDEyMzk3My0yMDI2LTA0LTIzLWVu/tiny/Cook-County-Health.png https://www.kentuckyhealthwire.com/article/907589540-hormify-launches-transparent-research-based-supplement-for-hormonal-balance-and-daily-wellness Kentucky Health Wire en PressRelease 2026-04-23T19:27:22+00:00 Hormify Launches Transparent, Research-Based Supplement for Hormonal Balance and Daily Wellness https://ml.globenewswire.com/media/e538c302-eeee-4287-9d09-5cc8e08f5b4c/small/555-jpg.jpg https://www.kentuckyhealthwire.com/article/907588094-ai-powered-nerve-monitoring-systems-poised-to-transform-surgical-safety-as-workforce-shortages-drive-remote-monitoring-adoption Kentucky Health Wire en PressRelease 2026-04-23T18:03:16+00:00 AI-Powered Nerve Monitoring Systems Poised to Transform Surgical Safety as Workforce Shortages Drive Remote Monitoring Adoption https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.kentuckyhealthwire.com/article/907587687-progyny-inc-announces-details-for-its-first-quarter-2026-results-report Kentucky Health Wire en PressRelease 2026-04-23T17:55:46+00:00 Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report https://ml.globenewswire.com/media/1342dacd-99c3-4043-af8a-2fd5e9ea569f/small/progyny-203860-no-tag-png.png https://www.kentuckyhealthwire.com/article/907570099-grace-therapeutics-provides-regulatory-update-on-new-drug-application-for-gtx-104 Kentucky Health Wire en PressRelease 2026-04-23T17:13:24+00:00 Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104 https://ml.globenewswire.com/media/c71c0a95-caed-4520-87a9-ac7fefef3f07/small/grce-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907570032-otarmeni-lunsotogene-parvec-cwha-approved-by-fda-as-first-and-only-gene-therapy-for-genetic-hearing-loss-regeneron-to-provide-otarmeni-for-free-in Kentucky Health Wire en PressRelease 2026-04-23T16:40:00+00:00 Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S. https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907569967-pridcor-therapeutics-secures-global-antiviral-portfolio-establishing-leadership-in-treatment-of-long-covid-and-infection-associated-chronic-illnesses Kentucky Health Wire en PressRelease 2026-04-23T16:14:40+00:00 PridCor Therapeutics Secures Global Antiviral Portfolio, Establishing Leadership in Treatment of Long COVID and Infection-Associated Chronic Illnesses https://ml.globenewswire.com/media/c6e61521-f249-47fc-ba7e-29e8c1ed809f/small/untitled-design-png.png https://www.kentuckyhealthwire.com/article/907567815-orchestra-biomed-to-present-avim-therapy-clinical-and-mechanistic-data-at-hrs-2026 Kentucky Health Wire en PressRelease 2026-04-23T16:00:00+00:00 Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026 https://ml.globenewswire.com/media/00697d05-bd34-4570-822b-f204caf21694/small/ogsk2sgeyptxenjnnf5a-png.png https://www.kentuckyhealthwire.com/article/907568034-catheter-precision-to-attend-and-share-new-clinical-data-at-the-47th-annual-heart-rhythm-society-meeting Kentucky Health Wire en PressRelease 2026-04-23T16:00:00+00:00 Catheter Precision to Attend and Share New Clinical Data at the 47th Annual Heart Rhythm Society Meeting https://ml.globenewswire.com/media/cb9f10dc-be78-4c7c-a235-81bfdd77f03c/small/catheterlogo-jpg.jpg https://www.kentuckyhealthwire.com/article/907566642-chiffre-d-affaires-du-1er-trimestre-2026 Kentucky Health Wire en PressRelease 2026-04-23T15:45:00+00:00 Chiffre d’affaires du 1er trimestre 2026 https://ml-eu.globenewswire.com/media/c4731c25-21f2-47d1-910e-edbaeb4de604/small/ https://www.kentuckyhealthwire.com/article/907566874-q1-2026-revenue Kentucky Health Wire en PressRelease 2026-04-23T15:45:00+00:00 Q1 2026 revenue https://ml-eu.globenewswire.com/media/c4731c25-21f2-47d1-910e-edbaeb4de604/small/logo-color-cmjn-bd-jpg.jpg https://www.kentuckyhealthwire.com/article/907549633-fsr-in-partnership-with-ats-welcomes-dr-matt-craig-to-drive-strategic-research-initiatives Kentucky Health Wire en PressRelease 2026-04-23T14:35:37+00:00 FSR, in Partnership with ATS, Welcomes Dr. Matt Craig to Drive Strategic Research Initiatives https://ml.globenewswire.com/media/cb9862de-da73-457c-922e-18812ff4e604/medium/j-matt-craig-phd-joins-fsr-and-ats.png https://www.kentuckyhealthwire.com/article/907546299-new-data-quantifies-the-nasm-premium-certified-professionals-earn-22-more-than-industry-peers Kentucky Health Wire en PressRelease 2026-04-23T14:34:00+00:00 New Data Quantifies the "NASM Premium": Certified Professionals Earn 22% More Than Industry Peers https://ml.globenewswire.com/media/ZDk4NDBjYzYtNmUyOC00ZTQ1LTk2ZjgtNzY0OWVlMWRmM2YxLTEyNjU1NTctMjAyNi0wNC0yMy1lbg==/tiny/The-National-Academy-of-Sports.png https://www.kentuckyhealthwire.com/article/907549599-mother-s-day-gift-ideas-for-moms-experiential-gifts-like-cooking-together-trending-in-2026 Kentucky Health Wire en PressRelease 2026-04-23T14:26:07+00:00 Mother’s Day Gift Ideas for Moms: Experiential Gifts Like Cooking Together Trending in 2026 https://ml.globenewswire.com/media/N2IwYmVlZjktN2JjOC00Njk5LWIxZmEtMzJhMGQwZWZjYzVlLTEzMjI2OTEtMjAyNi0wNC0yMy1lbg==/tiny/Raddish-Kids-Inc-.png https://www.kentuckyhealthwire.com/article/907546830-the-center-for-cancer-and-blood-disorders-receives-authorization-to-administer-fda-approved-car-t-cell-therapy-begins-treating-first-community Kentucky Health Wire en PressRelease 2026-04-23T14:05:00+00:00 The Center for Cancer and Blood Disorders receives authorization to administer FDA-approved CAR T-cell therapy; begins treating first community oncology patient in Maryland-area clinic https://ml.globenewswire.com/media/bb25f585-c65f-49ae-833e-6a3c04e2e01c/medium/the-center-for-cancer-and-blood-disorders-receives-authoriza.png https://www.kentuckyhealthwire.com/article/907549514-verano-founder-and-chief-executive-officer-george-archos-celebrates-historic-announcement-confirming-cannabis-rescheduling-to-schedule-iii Kentucky Health Wire en PressRelease 2026-04-23T13:55:00+00:00 Verano Founder and Chief Executive Officer George Archos Celebrates Historic Announcement Confirming Cannabis Rescheduling to Schedule III https://ml.globenewswire.com/media/18f2c9e0-d960-440b-a51f-b7d7ea7c9e08/small/verano-company-logo-png.png https://www.kentuckyhealthwire.com/article/907549410-jushi-holdings-inc-applauds-president-trump-and-administration-for-delivering-on-cannabis-rescheduling-to-schedule-iii-under-the-controlled Kentucky Health Wire en PressRelease 2026-04-23T13:43:18+00:00 Jushi Holdings Inc. Applauds President Trump and Administration for Delivering on Cannabis Rescheduling to Schedule III under the Controlled Substances Act https://ml.globenewswire.com/media/e65f15fd-322c-4847-83c5-ceafe27f97d5/small/jushi-png.png https://www.kentuckyhealthwire.com/article/907547420-lumina-therapy-alliance-expands-silicon-valley-presence-with-addition-of-wise-mind-institute-in-redwood-city-ca Kentucky Health Wire en PressRelease 2026-04-23T13:40:00+00:00 Lumina Therapy Alliance Expands Silicon Valley Presence with Addition of Wise Mind Institute in Redwood City, CA https://ml.globenewswire.com/media/046b4a15-6585-4d91-936e-8041854f2835/small/lumina-logo-li-1-png.png https://www.kentuckyhealthwire.com/article/907548326-innocare-releases-2026-q1-results-strong-revenue-growth-and-sustained-profitability Kentucky Health Wire en PressRelease 2026-04-23T13:20:49+00:00 InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability https://ml.globenewswire.com/media/2dc70b00-a0b0-4d85-adef-2717a7067aec/small/innocare-eng-logo-horizontal-png.png https://www.kentuckyhealthwire.com/article/907545780-women-are-ditching-generic-diets-for-cycle-based-wellness-this-cycle-diet-app-review-explains-why Kentucky Health Wire en PressRelease 2026-04-23T13:15:00+00:00 Women Are Ditching Generic Diets for Cycle-Based Wellness – This Cycle Diet App Review Explains Why https://ml-eu.globenewswire.com/media/70993e65-50d6-4174-b0c0-529713dd084f/medium/cycle-diet-cycle-based-weight-loss-program.png https://www.kentuckyhealthwire.com/article/907548102-leading-kidney-organizations-unite-on-capitol-hill-for-kidney-diseases-the-hidden-crisis-in-american-health-care-congressional-briefing Kentucky Health Wire en PressRelease 2026-04-23T13:14:54+00:00 Leading Kidney Organizations Unite on Capitol Hill for “Kidney Diseases: The Hidden Crisis in American Health Care” Congressional Briefing https://ml.globenewswire.com/media/MjQwZmE4YjctZmI0OS00NTljLThhY2MtMTM5ZmNiNjdiYzYxLTExMDkwNTItMjAyNi0wNC0yMy1lbg==/tiny/American-Kidney-Fund.png https://www.kentuckyhealthwire.com/article/907538473-alpha-tau-announces-fda-approval-of-ide-supplement-to-expand-alpha-dart-impact-trial-to-patients-with-pancreatic-cancer-receiving-gemcitabine-with Kentucky Health Wire en PressRelease 2026-04-23T13:02:00+00:00 Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel) https://ml.globenewswire.com/media/a9de6f03-a487-4934-98e9-d25cdb4c8bed/small/atm-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907536253-alpha-tau-successfully-treats-first-pancreatic-cancer-patient-in-europe-with-alpha-dart-in-french-multicenter-acapella-clinical-trial Kentucky Health Wire en PressRelease 2026-04-23T13:01:00+00:00 Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial https://ml.globenewswire.com/media/a9de6f03-a487-4934-98e9-d25cdb4c8bed/small/atm-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907526664-philips-launches-new-bridge-plus-occlusion-balloon-to-help-manage-rare-but-life-threatening-svc-tears-during-lead-extraction Kentucky Health Wire en PressRelease 2026-04-23T13:00:00+00:00 Philips launches new Bridge Plus Occlusion Balloon to help manage rare but life-threatening SVC tears during lead extraction https://ml-eu.globenewswire.com/media/e5826782-01bc-45e7-b448-9ca1eae0125e/small/philips-logo-logotype-emblem-700x128-png.png https://www.kentuckyhealthwire.com/article/907529427-neura-health-to-expand-access-to-migraine-care-via-lillydirect Kentucky Health Wire en PressRelease 2026-04-23T13:00:00+00:00 Neura Health to Expand Access to Migraine Care via LillyDirect https://ml.globenewswire.com/media/306a1f86-8530-49f8-aa6b-3c6364cbcde1/small/neura-logo-png.png https://www.kentuckyhealthwire.com/article/907531469-neocis-and-yomi-s-named-winner-of-the-2026-tag-awards-for-medtech-in-robotic-procedural-innovation Kentucky Health Wire en PressRelease 2026-04-23T13:00:00+00:00 Neocis and Yomi® S Named Winner of the 2026 TAG Awards for MedTech in Robotic & Procedural Innovation https://ml.globenewswire.com/media/b2a5a1e1-cc7c-4d46-8ac3-c0f2a3682be2/small/neocis-alternate-png.png https://www.kentuckyhealthwire.com/article/907532046-dogwood-therapeutics-announces-worldwide-development-and-commercialization-partnership-for-anti-viral-assets-with-potential-value-up-to-100m Kentucky Health Wire en PressRelease 2026-04-23T13:00:00+00:00 Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M https://ml.globenewswire.com/media/7fe5cc47-6599-477c-a858-0f0d9b9f7eb5/small/green-and-gray-png.png https://www.kentuckyhealthwire.com/article/907532364-connect-biopharma-announces-enrollment-in-phase-2-seabreeze-stat-studies-will-continue-as-planned-following-pre-specified-interim-analysis Kentucky Health Wire en PressRelease 2026-04-23T13:00:00+00:00 Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis https://ml.globenewswire.com/media/831dcc2a-691d-4cad-813e-855f9fa2bd69/small/connect-logo-cmyk-jpg.jpg https://www.kentuckyhealthwire.com/article/907532701-maps-celebrates-40-years-at-a-defining-moment-for-psychedelics Kentucky Health Wire en PressRelease 2026-04-23T13:00:00+00:00 MAPS Celebrates 40 Years at a Defining Moment for Psychedelics https://ml.globenewswire.com/media/4f774750-4742-4818-be22-116e2b2085b1/small/maps-logo-2021-primary-horizontal-white-background-1200x486.jpg https://www.kentuckyhealthwire.com/article/907534875-codexis-to-report-first-quarter-2026-financial-results-on-may-7 Kentucky Health Wire en PressRelease 2026-04-23T13:00:00+00:00 Codexis to Report First Quarter 2026 Financial Results on May 7 https://ml.globenewswire.com/media/ebbfa755-c2db-4783-aace-43c700ba3369/small/codexis-logo-september-2023-png.png https://www.kentuckyhealthwire.com/article/907538601-h1-launches-site-network-suite-the-first-ai-powered-platform-to-transform-how-research-sites-and-sponsors-engage-on-clinical-trials Kentucky Health Wire en PressRelease 2026-04-23T13:00:00+00:00 H1 Launches Site Network Suite, the First AI-Powered Platform to Transform How Research Sites and Sponsors Engage on Clinical Trials https://ml.globenewswire.com/media/dc362fcf-5008-429c-bf37-cf26402cd802/small/h1-logo-primary-4x-21-png.png https://www.kentuckyhealthwire.com/article/907538664-heald-partners-with-thatch-marketplace-to-bring-first-of-its-kind-diabetes-reversal-program-to-employees Kentucky Health Wire en PressRelease 2026-04-23T13:00:00+00:00 Heald Partners with Thatch Marketplace to Bring First-of-its-Kind Diabetes Reversal Program to Employees https://ml.globenewswire.com/media/5ed5f22c-5871-49c8-b232-ab058a530369/small/heald-logo-2-png.png https://www.kentuckyhealthwire.com/article/907538714-tilray-brands-positioned-for-u-s-expansion-amid-historic-cannabis-rescheduling Kentucky Health Wire en PressRelease 2026-04-23T12:53:52+00:00 Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling https://ml.globenewswire.com/media/2dbf85bb-5e30-4623-8f9b-931442240c05/small/tilraybrands-logo-fullcolor-rbg-horiz-01-png.png https://www.kentuckyhealthwire.com/article/907530858-ritedose-university-of-south-carolina-welcome-top-european-business-students-for-immersive-learning-about-advanced-manufacturing Kentucky Health Wire en PressRelease 2026-04-23T12:37:00+00:00 Ritedose, University of South Carolina Welcome Top European Business Students for Immersive Learning about Advanced Manufacturing https://ml.globenewswire.com/media/7d397bb5-f152-4003-abe7-88a69feaf034/medium/ritedose-university-in-action.jpg https://www.kentuckyhealthwire.com/article/907527341-vericel-to-report-first-quarter-2026-financial-results-on-may-7-2026 Kentucky Health Wire en PressRelease 2026-04-23T12:30:00+00:00 Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026 https://ml.globenewswire.com/media/6a144258-8523-493f-8a1e-ccceec233208/small/vericel-corporation-logo.jpg https://www.kentuckyhealthwire.com/article/907527777-icu-medical-announces-time-of-first-quarter-2026-earnings-conference-call Kentucky Health Wire en PressRelease 2026-04-23T12:30:00+00:00 ICU Medical Announces Time of First Quarter 2026 Earnings Conference Call https://ml.globenewswire.com/media/44f52bc4-1355-405c-bdac-609254095f19/small/icu-medical-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907530786-cytodyn-to-host-investor-webcast Kentucky Health Wire en PressRelease 2026-04-23T12:30:00+00:00 CytoDyn to Host Investor Webcast https://ml.globenewswire.com/media/3b426b4d-6299-4c23-9f95-058174a5b7be/small/new-logo-png.png https://www.kentuckyhealthwire.com/article/907531167-renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco Kentucky Health Wire en PressRelease 2026-04-23T12:30:00+00:00 RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting https://ml.globenewswire.com/media/e18bf823-ff44-4bbd-82b9-3a311d58dad8/small/final-logo-horizontal-png.png https://www.kentuckyhealthwire.com/article/907531450-ss-innovations-unveils-cutting-edge-surgical-robotic-technologies-at-smrsc-2026 Kentucky Health Wire en PressRelease 2026-04-23T12:30:00+00:00 SS Innovations Unveils Cutting-Edge Surgical Robotic Technologies at SMRSC 2026 https://ml.globenewswire.com/media/5ab9180b-915c-4e02-838c-f5a9e458e61d/medium/ssi-vimana-aero-drone-system.png https://www.kentuckyhealthwire.com/article/907531754-enlivex-to-present-phase-iia-3-month-and-6-month-data-of-allocetra-at-oarsi-2026-world-congress Kentucky Health Wire en PressRelease 2026-04-23T12:30:00+00:00 Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress https://ml.globenewswire.com/media/27d4e006-8709-4fd1-8341-5b58381487d4/small/picture1-jpg.jpg https://www.kentuckyhealthwire.com/article/907531972-polaryx-therapeutics-to-participate-in-national-tay-sachs-allied-diseases-association-annual-family-conference Kentucky Health Wire en PressRelease 2026-04-23T12:30:00+00:00 Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference https://ml.globenewswire.com/media/64e2f507-40e8-46aa-b22e-6661e7035467/small/polaryx-logonew-png.png https://www.kentuckyhealthwire.com/article/907535034-oncotelic-therapeutics-inc-otcqb-otlc-real-world-example-of-scientific-advancement-influence-on-evaluation Kentucky Health Wire en PressRelease 2026-04-23T12:30:00+00:00 Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation https://ml.globenewswire.com/media/aa650511-a1c3-496e-803a-448d7f8d409a/small/picture1-jpg.jpg https://www.kentuckyhealthwire.com/article/907531463-moleculin-s-annamycin-extends-survival-by-more-than-60-in-metastatic-pancreatic-cancer-preclinical-models-data-presented-at-aacr-2026 Kentucky Health Wire en PressRelease 2026-04-23T12:25:00+00:00 Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026 https://ml.globenewswire.com/media/7fa09722-2ef8-49fc-bc24-6b150093f8ba/small/mbrx-logo-png.png https://www.kentuckyhealthwire.com/article/907531366-noom-health-s-smartrx-program-on-track-to-cut-employer-s-glp-1-spend-by-nearly-80 Kentucky Health Wire en PressRelease 2026-04-23T12:01:00+00:00 Noom Health’s SmartRx Program on Track to Cut Employer’s GLP-1 Spend by Nearly 80% https://ml.globenewswire.com/media/MjVlZDBjOGYtYzVjZC00ZDkxLWE1NTItMmY3MjQzNDczOTNjLTEyMTc3NDctMjAyNi0wNC0yMy1lbg==/tiny/Noom-Inc.png https://www.kentuckyhealthwire.com/article/907537792-ardelyx-announces-abstract-exploring-ibs-c-treatment-patterns-accepted-for-poster-presentation-at-digestive-disease-week-2026 Kentucky Health Wire en PressRelease 2026-04-23T12:01:00+00:00 Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026 https://ml.globenewswire.com/media/cee4ae6d-7a85-44bf-9c02-87e7fa934ec2/small/ardelyx-logo-rgb-jpg.jpg https://www.kentuckyhealthwire.com/article/907527434-collegium-to-report-first-quarter-2026-financial-results-on-may-7-2026 Kentucky Health Wire en PressRelease 2026-04-23T12:00:00+00:00 Collegium to Report First Quarter 2026 Financial Results on May 7, 2026 https://ml.globenewswire.com/media/c9077b27-1a69-42a5-9f77-e39124f4d2a2/small/collegium-rgb-large-r-jpg.jpg https://www.kentuckyhealthwire.com/article/907528111-apyx-medical-corporation-to-release-first-quarter-of-fiscal-year-2026-financial-results-on-may-7-2026 Kentucky Health Wire en PressRelease 2026-04-23T12:00:00+00:00 Apyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026 https://ml.globenewswire.com/media/aa0687d3-ab28-4615-b1e7-ef6c6e2a5541/small/apyx-medical-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907528957-electrocore-product-line-featured-in-documentary-underscoring-the-expanding-clinical-and-commercial-role-of-vagus-nerve-stimulation Kentucky Health Wire en PressRelease 2026-04-23T12:00:00+00:00 electroCore Product Line Featured in Documentary Underscoring the Expanding Clinical and Commercial Role of Vagus Nerve Stimulation https://ml.globenewswire.com/media/b80ed5b6-a449-461c-9034-85386286b09d/small/ec-logo-2018-tm-cmyk-jpg.jpg https://www.kentuckyhealthwire.com/article/907529926-mbx-biosciences-to-host-in-person-and-virtual-obesity-day-on-may-11-2026-to-discuss-expanding-obesity-portfolio Kentucky Health Wire en PressRelease 2026-04-23T12:00:00+00:00 MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio https://ml.globenewswire.com/media/5499b327-bce0-4a3f-96a7-04a38b68a99f/small/mbx-logos-final-full-jpg.jpg https://www.kentuckyhealthwire.com/article/907530330-atsena-therapeutics-announces-upcoming-presentations-at-scientific-and-medical-meetings Kentucky Health Wire en PressRelease 2026-04-23T12:00:00+00:00 Atsena Therapeutics Announces Upcoming Presentations at Scientific and Medical Meetings https://ml.globenewswire.com/media/90d0bd84-4404-435c-9875-3473b4cc7172/small/atsena-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907533502-nanox-signs-distribution-agreement-with-radiology-oncology-systems-to-expand-nanox-arc-adoption-in-the-united-states Kentucky Health Wire en PressRelease 2026-04-23T12:00:00+00:00 Nanox Signs Distribution Agreement with Radiology Oncology Systems to Expand Nanox.ARC Adoption in the United States https://ml.globenewswire.com/media/57c1ffd6-84b3-46b9-b9b3-76666e6ba5a2/small/nano-logo-002-jpg.jpg https://www.kentuckyhealthwire.com/article/907533837-reviva-to-participate-in-a-fireside-chat-hosted-by-a-g-p-on-brilaroxazine-s-potential-across-multiple-neuropsychiatric-indications Kentucky Health Wire en PressRelease 2026-04-23T12:00:00+00:00 Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications https://ml.globenewswire.com/media/1d8c6564-1da5-4561-b6ec-79de6d565869/small/reviva-logo-png.png https://www.kentuckyhealthwire.com/article/907536072-theialife-appoints-thomas-ruggia-as-president-and-chief-executive-officer-to-advance-phase-3-ready-oral-myopia-therapy-and-scale-ophthalmology Kentucky Health Wire en PressRelease 2026-04-23T12:00:00+00:00 Theialife Appoints Thomas Ruggia as President and Chief Executive Officer to Advance Phase-3 Ready Oral Myopia Therapy and Scale Ophthalmology Platform https://ml.globenewswire.com/media/7d66d72f-7dd8-41c5-8f9a-f17bf09572c6/small/theialife-logo-png.png https://www.kentuckyhealthwire.com/article/907537011-belite-bio-to-participate-in-four-upcoming-investor-conferences Kentucky Health Wire en PressRelease 2026-04-23T12:00:00+00:00 Belite Bio to Participate in Four Upcoming Investor Conferences https://ml.globenewswire.com/media/7f86ac70-6347-41c6-a622-e7000c42ad35/small/belite-bio-logo-digital-full-color-png.png https://www.kentuckyhealthwire.com/article/907537024-cortec-s-brain-interchange-accepted-into-fda-total-product-life-cycle-advisory-program-tap Kentucky Health Wire en PressRelease 2026-04-23T12:00:00+00:00 CorTec’s Brain Interchange™ Accepted into FDA Total Product Life Cycle Advisory Program (TAP) https://ml.globenewswire.com/media/b24bcd60-c029-415f-bcfd-277fade5e278/small/cortec-logo-tm-sub-rgb-transp-png.png https://www.kentuckyhealthwire.com/article/907528164-gb-healthwatch-launches-ai-ready-genetic-reports-for-the-gb-longevity100-suite Kentucky Health Wire en PressRelease 2026-04-23T11:47:00+00:00 GB HealthWatch Launches AI-Ready Genetic Reports for the GB Longevity100 Suite https://ml.globenewswire.com/media/fccad032-0535-44e1-b7f1-b846db3ea3b7/medium/genomics-ai-for-longevity.jpg https://www.kentuckyhealthwire.com/article/907529388-marvel-biosciences-to-participate-and-present-at-the-2nd-neuroscience-innovation-partnering-and-licensing-summit Kentucky Health Wire en PressRelease 2026-04-23T11:30:00+00:00 Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit https://ml.globenewswire.com/media/d49e32dc-88d9-4694-a3dd-6e663548e80d/small/picture1-png.png https://www.kentuckyhealthwire.com/article/907529549-plus-therapeutics-initiates-manufacturing-activities-with-spectronrx-under-a-master-services-agreement-to-support-gmp-pivotal-trial-readiness-for Kentucky Health Wire en PressRelease 2026-04-23T11:30:00+00:00 Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™ https://ml.globenewswire.com/media/92d7aa70-e37d-4870-bccf-d83b68ba5612/small/plus-logo-png.png https://www.kentuckyhealthwire.com/article/907531773-corvus-pharmaceuticals-appoints-andrew-c-chan-m-d-ph-d-to-board-of-directors Kentucky Health Wire en PressRelease 2026-04-23T11:30:00+00:00 Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors https://ml.globenewswire.com/media/d05c16d1-5c24-4242-84b5-aea3951ca251/small/corvus-logo-large-jpg.jpg https://www.kentuckyhealthwire.com/article/907532602-helus-pharma-strengthens-scientific-advisory-board-with-addition-of-dr-robert-langer-and-dr-stephen-brannan Kentucky Health Wire en PressRelease 2026-04-23T11:30:00+00:00 Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan https://ml.globenewswire.com/media/575a4e81-a546-4d83-a092-e8f0df765900/small/hp-pms-with-margins-png.png https://www.kentuckyhealthwire.com/article/907530935-aurora-spine-corporation-schedules-release-of-fourth-quarter-and-fiscal-2025-financial-results Kentucky Health Wire en PressRelease 2026-04-23T11:15:00+00:00 Aurora Spine Corporation Schedules Release of Fourth Quarter and Fiscal 2025 Financial Results https://ml.globenewswire.com/media/af1a0a7b-b883-41f9-8c86-a89bad3cc4a4/small/aurora12-jpg.JPG https://www.kentuckyhealthwire.com/article/907529456-the-joint-corp-to-report-2026-first-quarter-results-on-thursday-may-7-and-host-conference-call-and-webcast Kentucky Health Wire en PressRelease 2026-04-23T11:05:00+00:00 The Joint Corp. to Report 2026 First Quarter Results on Thursday, May 7 and Host Conference Call and Webcast https://ml.globenewswire.com/media/ca375acf-3959-4292-8efa-e64eeeca3ed0/small/jynt-792x612px-1-png.png https://www.kentuckyhealthwire.com/article/907530793-ocugen-to-present-at-april-2026-investor-and-industry-conferences Kentucky Health Wire en PressRelease 2026-04-23T11:02:00+00:00 Ocugen to Present at April 2026 Investor and Industry Conferences https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png https://www.kentuckyhealthwire.com/article/907526315-radiopharm-theranostics-reports-business-update Kentucky Health Wire en PressRelease 2026-04-23T11:00:00+00:00 Radiopharm Theranostics Reports Business Update https://ml-eu.globenewswire.com/media/8e246920-183e-46a4-b13c-a3c9ec50ada9/small/radx-logo-png.png https://www.kentuckyhealthwire.com/article/907526650-genenta-signs-definitive-agreements-with-sophia-high-tech Kentucky Health Wire en PressRelease 2026-04-23T11:00:00+00:00 Genenta signs Definitive Agreements with Sophia High Tech https://ml-eu.globenewswire.com/media/512cd33c-8299-4f88-9053-ae862103eb0e/small/genenta-logo-positivo-png.png https://www.kentuckyhealthwire.com/article/907526659-antag-therapeutics-to-present-data-on-at7687-its-first-in-class-gipr-antagonist-peptide-at-the-american-diabetes-association-s-2026-scientific Kentucky Health Wire en PressRelease 2026-04-23T11:00:00+00:00 Antag Therapeutics to present data on AT7687, its first-in-class GIPR antagonist peptide at the American Diabetes Association’s 2026 Scientific Sessions https://ml-eu.globenewswire.com/media/5001e437-9bc0-482c-9bee-3be9c9f71505/small/antag-logo-black-rgb-jpg.jpg https://www.kentuckyhealthwire.com/article/907528725-kymera-therapeutics-to-report-first-quarter-2026-financial-results-on-april-30-2026 Kentucky Health Wire en PressRelease 2026-04-23T11:00:00+00:00 Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026 https://ml.globenewswire.com/media/4d3d3283-c57d-401e-9e1b-53f17e22d76b/small/kymera-logo-rgb-denim-marigold-high-res-png.png https://www.kentuckyhealthwire.com/article/907529147-tonix-pharmaceuticals-presents-updates-on-preclinical-immuno-oncology-programs-at-the-american-association-for-cancer-research-aacr-annual-meeting Kentucky Health Wire en PressRelease 2026-04-23T11:00:00+00:00 Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026 https://ml.globenewswire.com/media/16aad249-3d33-4501-b3d9-118a703fa46e/small/tonix2-jpg.jpg https://www.kentuckyhealthwire.com/article/907529376-aafa-highlights-new-resources-for-nasal-polyps-in-recognition-of-global-crswnp-awareness-day Kentucky Health Wire en PressRelease 2026-04-23T11:00:00+00:00 AAFA Highlights New Resources for Nasal Polyps in Recognition of Global CRSwNP Awareness Day https://ml.globenewswire.com/media/ZGIxMDA1MTUtZWIyZi00MmRkLWEzNzctNzY5NGI2ZWY4MTU3LTExMDE5NjItMjAyNi0wNC0yMy1lbg==/tiny/Asthma-and-Allergy-Foundation-.png https://www.kentuckyhealthwire.com/article/907530148-conavi-medical-awarded-2026-tag-innovation-award Kentucky Health Wire en PressRelease 2026-04-23T11:00:00+00:00 Conavi Medical Awarded 2026 TAG Innovation Award https://ml.globenewswire.com/media/4a28f1c0-f99d-4940-b2a7-201ab98cdaff/small/conavi-jpg.jpg https://www.kentuckyhealthwire.com/article/907530670-jade-biosciences-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4 Kentucky Health Wire en PressRelease 2026-04-23T11:00:00+00:00 Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/74b5b00e-9a9e-4581-801b-a6e2ddab3aab/small/jade-logo-full-color-rgb-jpg.jpg https://www.kentuckyhealthwire.com/article/907530835-psyence-biomed-initiates-patient-dosing-in-phase-iib-trial-evaluating-npx-5-for-adjustment-disorder Kentucky Health Wire en PressRelease 2026-04-23T11:00:00+00:00 Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder https://ml.globenewswire.com/media/256a2527-4c30-46a1-a4d4-f37c89cfbff2/small/psyence-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907531417-verano-expands-retail-presence-on-florida-s-emerald-coast-with-opening-of-m-v-miramar-beach-the-company-s-85th-florida-dispensary-and-162nd-location Kentucky Health Wire en PressRelease 2026-04-23T11:00:00+00:00 Verano Expands Retail Presence on Florida’s Emerald Coast with Opening of MÜV Miramar Beach, the Company’s 85th Florida Dispensary and 162nd Location Nationwide https://ml.globenewswire.com/media/18f2c9e0-d960-440b-a51f-b7d7ea7c9e08/small/verano-company-logo-png.png https://www.kentuckyhealthwire.com/article/907532361-brewdog-usa-doubles-down-on-headliners-and-ignites-next-wave-of-innovation-for-spring-and-summer Kentucky Health Wire en PressRelease 2026-04-23T11:00:00+00:00 BrewDog USA Doubles Down on Headliners and Ignites Next Wave of Innovation for Spring and Summer https://ml.globenewswire.com/media/d423c9fd-1d8f-4ea0-bf36-4f5c40fa13e7/medium/brewdog-elvis-juice.jpg https://www.kentuckyhealthwire.com/article/907532569-validic-launches-free-developer-tier-with-api-driven-agentic-ready-self-signup Kentucky Health Wire en PressRelease 2026-04-23T11:00:00+00:00 Validic Launches Free Developer Tier with API-Driven, Agentic-Ready Self-Signup https://ml.globenewswire.com/media/5c89ea69-9ba7-4994-a816-9e0fe1f95b46/small/validic-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907535459-transcenta-therapeutics-presents-new-data-for-its-novel-liv1-targeting-adc-tst013-demonstrating-potent-anti-tumor-activity-in-pdx-models-of-prostate Kentucky Health Wire en PressRelease 2026-04-23T11:00:00+00:00 Transcenta Therapeutics Presents New Data for its Novel LIV1-Targeting ADC TST013 Demonstrating Potent Anti-Tumor Activity in PDX Models of Prostate Cancer and ER Positive /HER2 Negative Breast Cancer https://ml.globenewswire.com/media/N2E2ZDY4ZjItMTU5My00ZTQ3LTkzZWUtZjdmMDFjODNkOGVjLTEzMDM2NDAtMjAyNi0wNC0yMy1lbg==/tiny/Transcenta.png https://www.kentuckyhealthwire.com/article/907535959-aavantgarde-to-participate-in-arvo-2026-with-presentations-at-key-pre-events-and-new-clinical-data-from-the-luce-phase-1-2-study Kentucky Health Wire en PressRelease 2026-04-23T11:00:00+00:00 AAVantgarde to Participate in ARVO 2026, with Presentations at Key Pre-events and New Clinical Data from the LUCE Phase 1/2 Study https://ml.globenewswire.com/media/e7ffd915-8158-436d-b9fe-8db1cb3597ce/small/logo-png.png https://www.kentuckyhealthwire.com/article/907507667-aveanna-announces-first-quarter-2026-earnings-release-date-and-conference-call Kentucky Health Wire en PressRelease 2026-04-23T10:30:00+00:00 Aveanna Announces First Quarter 2026 Earnings Release Date and Conference Call https://ml.globenewswire.com/media/d3896f9e-a6a1-48c1-a8f7-d9ba5d7433d6/small/aveanna-healthcare-500x262-png.png https://www.kentuckyhealthwire.com/article/907508353-greenwich-lifesciences-announces-acceptance-of-abstract-at-asco-2026 Kentucky Health Wire en PressRelease 2026-04-23T10:00:00+00:00 Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026 https://ml.globenewswire.com/media/e0bfd967-b05f-43d2-91b4-d2a5d551df99/small/logo-edited-jpg.jpg https://www.kentuckyhealthwire.com/article/907489700-epitopea-announces-approval-of-ovact-clinical-trial-application-for-cryptivax-1001-in-advanced-high-grade-serous-ovarian-cancer Kentucky Health Wire en PressRelease 2026-04-23T08:00:00+00:00 Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer https://ml.globenewswire.com/media/e42e44d9-eec5-4ff3-a9ee-fab395efd2a8/small/epitopea-instagram-post-2-jpg.jpg https://www.kentuckyhealthwire.com/article/907489827-nectero-therapeutics-reports-two-year-safety-and-efficacy-data-from-first-in-human-trial-for-treatment-of-small-to-medium-sized-abdominal-aortic Kentucky Health Wire en PressRelease 2026-04-23T08:00:00+00:00 Nectero Therapeutics Reports Two-Year Safety and Efficacy Data from First-in-Human Trial for Treatment of Small- to Medium-Sized Abdominal Aortic Aneurysms https://ml.globenewswire.com/media/925156fd-7767-4c7b-b969-3584da050fbb/small/nectero-therapeutics-logo-horizontal-centered-png.png https://www.kentuckyhealthwire.com/article/907489911-ena-respiratory-appoints-melissa-faris-to-board Kentucky Health Wire en PressRelease 2026-04-23T08:00:00+00:00 ENA Respiratory Appoints Melissa Faris to Board https://ml-eu.globenewswire.com/media/84159208-c519-49a5-86c6-56151e3ab92b/small/ena-png.png https://www.kentuckyhealthwire.com/article/907490272-epitopea-annonce-l-approbation-de-la-demande-d-essai-clinique-ovact-pour-le-cryptivax-1001-dans-le-cancer-de-l-ovaire-s-reux-de-haut-grade-avanc Kentucky Health Wire en PressRelease 2026-04-23T08:00:00+00:00 Epitopea annonce l'approbation de la demande d'essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l'ovaire séreux de haut grade avancé https://ml.globenewswire.com/media/e42e44d9-eec5-4ff3-a9ee-fab395efd2a8/small/epitopea-instagram-post-2-jpg.jpg https://www.kentuckyhealthwire.com/article/907490040-last-patient-last-visit-completed-in-phase-i-clinical-trial-of-pulsesight-therapeutics-pst-611-treatment-for-dry-amd-geographic-atrophy-ga Kentucky Health Wire en PressRelease 2026-04-23T07:00:00+00:00 Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA) https://ml-eu.globenewswire.com/media/9f8ee53c-2465-4c3c-870e-4077c6a39edb/small/pulsesight-therapeutics-logo-horizontal-full-gradient-mark-0.png https://www.kentuckyhealthwire.com/article/907473525-orion-pharma-initiates-teadco-phase-1b-2-basket-trial-evaluating-odm-212-in-combination-with-standard-of-care-treatments-in-patients-with-select Kentucky Health Wire en PressRelease 2026-04-23T06:00:00+00:00 Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours https://ml-eu.globenewswire.com/media/9e6a027a-eb6c-4e34-993e-b8295e6d598d/small/orionpharma-rgb-press-releases-jpg.jpg https://www.kentuckyhealthwire.com/article/907473565-orion-pharma-on-aloittanut-teadco-faasi-1b-2-tutkimuksen-odm-212-molekyylill-yhdess-vakiintuneiden-hoitojen-kanssa-potilailla-joilla-on-tiettyj Kentucky Health Wire en PressRelease 2026-04-23T06:00:00+00:00 Orion Pharma on aloittanut TEADCO Faasi 1b/2 -tutkimuksen ODM-212-molekyylillä yhdessä vakiintuneiden hoitojen kanssa potilailla, joilla on tiettyjä pitkälle edenneitä kiinteitä kasvaimia https://ml-eu.globenewswire.com/media/9e6a027a-eb6c-4e34-993e-b8295e6d598d/small/ https://www.kentuckyhealthwire.com/article/907472537-ose-immunotherapeutics-annonce-la-pr-sentation-des-r-sultats-de-l-tude-de-phase-2-tedova-de-tedopi-dans-le-cancer-de-l-ovaire-au-congr-s-2026-de Kentucky Health Wire en PressRelease 2026-04-23T05:30:00+00:00 OSE Immunotherapeutics annonce la présentation des résultats de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire au Congrès 2026 de l’ASCO https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ https://www.kentuckyhealthwire.com/article/907472704-communiqu-de-presse-t1-2026-croissance-deux-chiffres-du-chiffre-d-affaires-et-du-bnpa Kentucky Health Wire en PressRelease 2026-04-23T05:30:00+00:00 Communiqué de presse : T1 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907472829-ose-immunotherapeutics-announces-presentation-of-tedova-phase-2-topline-results-of-tedopi-in-ovarian-cancer-at-the-asco-2026-meeting Kentucky Health Wire en PressRelease 2026-04-23T05:30:00+00:00 OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ose-logo-horizontal-rvb-png.png https://www.kentuckyhealthwire.com/article/907473075-press-release-q1-2026-double-digit-sales-and-business-eps-growth Kentucky Health Wire en PressRelease 2026-04-23T05:30:00+00:00 Press Release: Q1 2026: double-digit sales and business EPS growth https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907472300-santhera-ernennt-orlando-oliveira-zum-chief-executive-officer Kentucky Health Wire en PressRelease 2026-04-23T05:00:00+00:00 Santhera ernennt Orlando Oliveira zum Chief Executive Officer https://ml-eu.globenewswire.com/media/63cd960e-70ce-4ba8-8984-92f72954c235/small/ https://www.kentuckyhealthwire.com/article/907472306-santhera-appoints-orlando-oliveira-as-chief-executive-officer Kentucky Health Wire en PressRelease 2026-04-23T05:00:00+00:00 Santhera Appoints Orlando Oliveira as Chief Executive Officer https://ml-eu.globenewswire.com/media/63cd960e-70ce-4ba8-8984-92f72954c235/small/logo-jpg.JPG https://www.kentuckyhealthwire.com/article/907473115-ipsen-delivers-strong-sales-in-the-first-quarter-of-2026-and-confirms-its-full-year-guidance Kentucky Health Wire en PressRelease 2026-04-23T05:00:00+00:00 Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance https://ml-eu.globenewswire.com/media/81292fcc-6b3a-4e4a-a083-ea4191bf920a/small/ipsen-notified-website-1200x628pix-500kb-max-jpg.jpg https://www.kentuckyhealthwire.com/article/907473136-ipsen-enregistre-une-forte-croissance-de-ses-ventes-au-premier-trimestre-2026-et-confirme-ses-objectifs-annuels Kentucky Health Wire en PressRelease 2026-04-23T05:00:00+00:00 Ipsen enregistre une forte croissance de ses ventes au premier trimestre 2026 et confirme ses objectifs annuels https://ml-eu.globenewswire.com/media/81292fcc-6b3a-4e4a-a083-ea4191bf920a/small/ https://www.kentuckyhealthwire.com/article/907473143-addex-spin-out-company-neurosterix-on-track-to-complete-phase-1-clinical-study-of-ntx-253-for-schizophrenia-in-q2-2026 Kentucky Health Wire en PressRelease 2026-04-23T05:00:00+00:00 Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026 https://ml-eu.globenewswire.com/media/e6c12443-4244-46f9-909c-5ab241bbea41/small/logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907473584-nobelpreisverd-chtige-entdeckung-von-vectorbuilder-wissenschaftlern-deckt-grundlegende-entwicklungsmechanismen-auf Kentucky Health Wire en PressRelease 2026-04-23T05:00:00+00:00 Nobelpreisverdächtige Entdeckung von VectorBuilder-Wissenschaftlern deckt grundlegende Entwicklungsmechanismen auf https://ml.globenewswire.com/media/051ef275-dc49-4fe6-bf1c-5736d994e6d3/small/vectorbuilder-logo-en-png.png https://www.kentuckyhealthwire.com/article/907473586-une-d-couverte-susceptible-de-valoir-un-prix-nobel-par-les-scientifiques-de-vectorbuilder-r-v-le-les-m-canismes-fondamentaux-du-d-veloppement Kentucky Health Wire en PressRelease 2026-04-23T05:00:00+00:00 Une découverte susceptible de valoir un prix Nobel par les scientifiques de VectorBuilder révèle les mécanismes fondamentaux du développement https://ml.globenewswire.com/media/051ef275-dc49-4fe6-bf1c-5736d994e6d3/small/vectorbuilder-logo-en-png.png https://www.kentuckyhealthwire.com/article/907454943-new-funding-opportunities-pave-the-way-for-better-diagnostics-and-treatment-as-well-as-for-engineering-efficient-biosolutions-and-replacing-critical Kentucky Health Wire en PressRelease 2026-04-23T04:30:00+00:00 New funding opportunities pave the way for better diagnostics and treatment as well as for engineering efficient biosolutions and replacing critical and scarce resources https://ml-eu.globenewswire.com/media/MTU3MDQwYzAtNDM3Ni00MDRkLWI0ZGMtNGY5N2VmMDczMDM4LTcwMDAyNzU2OC0yMDI2LTA0LTIzLWVu/tiny/Novo-Nordisk-Foundation.png https://www.kentuckyhealthwire.com/article/907455370-altimmune-announces-pricing-of-225-million-oversubscribed-public-offering-of-securities Kentucky Health Wire en PressRelease 2026-04-23T03:25:00+00:00 Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities https://ml.globenewswire.com/media/362fbdfa-dc07-456c-9908-9e042540158a/small/altimmune-logo-png.png https://www.kentuckyhealthwire.com/article/907421195-exicure-announces-co-development-agreement-with-adbiotech-for-burixafor-gpc-100 Kentucky Health Wire en PressRelease 2026-04-22T23:54:21+00:00 Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100) https://ml.globenewswire.com/media/3a5f958d-422c-4a97-a96d-cf06f640b587/small/exicure-logo-final-full-color-072515-png.png https://www.kentuckyhealthwire.com/article/907404570-press-release-sanofi-and-regeneron-s-dupixent-approved-in-the-us-as-the-first-biologic-medicine-for-young-children-with-uncontrolled-chronic Kentucky Health Wire en PressRelease 2026-04-22T21:30:00+00:00 Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907404644-communiqu-de-presse-dupixent-d-velopp-par-sanofi-et-regeneron-a-t-approuv-aux-tats-unis-comme-tant-le-premier-m-dicament-biologique-pour Kentucky Health Wire en PressRelease 2026-04-22T21:30:00+00:00 Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907406205-dupixent-dupilumab-approved-in-the-u-s-as-the-first-biologic-medicine-for-young-children-with-uncontrolled-chronic-spontaneous-urticaria-csu Kentucky Health Wire en PressRelease 2026-04-22T21:30:00+00:00 Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU) https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.kentuckyhealthwire.com/article/907404484-george-medicines-new-england-journal-of-medicine-publishes-global-stroke-outcomes-trial-that-demonstrated-reduction-of-risk-for-recurrent-stroke-by Kentucky Health Wire en PressRelease 2026-04-22T21:00:00+00:00 George Medicines: New England Journal of Medicine publishes global stroke outcomes trial that demonstrated reduction of risk for recurrent stroke by almost 40% with GMRx2 in patients with previous intracerebral hemorrhage https://ml-eu.globenewswire.com/media/96c66748-e7e2-4d1b-9950-2dbc75f2be98/small/george-medicines-logo-jpg.JPG https://www.kentuckyhealthwire.com/article/907405686-greenwich-lifesciences-announces-receipt-of-nasdaq-notice-regarding-late-form-10-k-filing Kentucky Health Wire en PressRelease 2026-04-22T21:00:00+00:00 Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing https://ml.globenewswire.com/media/e0bfd967-b05f-43d2-91b4-d2a5d551df99/small/logo-edited-jpg.jpg https://www.kentuckyhealthwire.com/article/907405515-sight-sciences-announces-the-release-of-its-sustainability-report Kentucky Health Wire en PressRelease 2026-04-22T20:45:00+00:00 Sight Sciences Announces the Release of its Sustainability Report https://ml.globenewswire.com/media/e7536623-9fa4-42d0-896d-04ddb984ef4e/small/sght-logo-png.png https://www.kentuckyhealthwire.com/article/907389765-plus-therapeutics-reports-granting-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4 Kentucky Health Wire en PressRelease 2026-04-22T20:30:00+00:00 Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/92d7aa70-e37d-4870-bccf-d83b68ba5612/small/plus-logo-png.png https://www.kentuckyhealthwire.com/article/907392165-altimmune-announces-proposed-underwritten-public-offering-of-securities Kentucky Health Wire en PressRelease 2026-04-22T20:19:41+00:00 Altimmune Announces Proposed Underwritten Public Offering of Securities https://ml.globenewswire.com/media/362fbdfa-dc07-456c-9908-9e042540158a/small/altimmune-logo-png.png https://www.kentuckyhealthwire.com/article/907389823-dentsply-sirona-to-host-first-quarter-2026-conference-call-on-may-5 Kentucky Health Wire en PressRelease 2026-04-22T20:15:00+00:00 Dentsply Sirona to Host First Quarter 2026 Conference Call on May 5 https://ml.globenewswire.com/media/91e36dfa-44e3-4905-a186-3a988bd67ab8/small/dentsply-sirona-grey-80-black-rgb-jpg.JPG https://www.kentuckyhealthwire.com/article/907390739-silo-pharma-announces-strategic-business-expansion-into-multi-billion-dollar-ai-agent-market-with-acquisition-of-managed-ai-agent-platform-qwikagents Kentucky Health Wire en PressRelease 2026-04-22T20:15:00+00:00 Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents https://ml.globenewswire.com/media/3b635464-4382-4b8b-8175-39cc32e08050/small/logo-png.png https://www.kentuckyhealthwire.com/article/907391236-supernus-pharmaceuticals-to-announce-first-quarter-2026-financial-results-and-host-conference-call-on-may-5-2026 Kentucky Health Wire en PressRelease 2026-04-22T20:15:00+00:00 Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026 https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg https://www.kentuckyhealthwire.com/article/907389885-rxsight-inc-to-report-first-quarter-2026-financial-results-on-may-6 Kentucky Health Wire en PressRelease 2026-04-22T20:10:00+00:00 RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6 https://ml.globenewswire.com/media/48441335-c938-45ff-9355-ba8e331354e9/small/rxsight-globe-png.png https://www.kentuckyhealthwire.com/article/907390905-orasure-to-announce-first-quarter-2026-financial-results-and-host-earnings-call-on-may-6th Kentucky Health Wire en PressRelease 2026-04-22T20:10:00+00:00 OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th https://ml.globenewswire.com/media/713ef28e-6d0b-4156-a92f-397061b474cf/small/oti-wordmark-png.png https://www.kentuckyhealthwire.com/article/907389412-abivax-to-present-data-on-obefazimod-at-digestive-disease-week Kentucky Health Wire en PressRelease 2026-04-22T20:05:00+00:00 Abivax to Present Data on Obefazimod at Digestive Disease Week® https://ml-eu.globenewswire.com/media/5470cd7e-c1fe-402f-8673-925c82bbd2fb/small/abivax-logo-rgb-png.png https://www.kentuckyhealthwire.com/article/907389490-skinhealth-systems-inc-appoints-three-new-independent-directors-to-board Kentucky Health Wire en PressRelease 2026-04-22T20:05:00+00:00 SkinHealth Systems Inc. Appoints Three New Independent Directors to Board https://ml.globenewswire.com/media/187132d2-7aef-4a14-8cd2-07829cc11496/small/skinhealthsystems-logo-black-jpg.jpg https://www.kentuckyhealthwire.com/article/907389686-lifecore-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4 Kentucky Health Wire en PressRelease 2026-04-22T20:05:00+00:00 Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/ca940278-cc18-4a3f-93b7-d8a034c998c9/small/lifecore-corporate-logo-2c-png.png https://www.kentuckyhealthwire.com/article/907389732-petmeds-announces-strategic-partnership-with-rural-king-to-launch-pet-pharmacy-offering-across-retail-and-digital-channels Kentucky Health Wire en PressRelease 2026-04-22T20:05:00+00:00 PetMeds announces strategic partnership with Rural King to launch pet pharmacy offering across retail and digital channels https://ml.globenewswire.com/media/dac159be-c4f9-491f-baa3-811a3ee58631/small/petmeds-pm-green-png.png https://www.kentuckyhealthwire.com/article/907389826-bbot-presents-preclinical-data-demonstrating-pan-kras-inhibitor-bbo-11818-has-robust-anti-tumor-activity-in-kras-mutant-preclinical-models-at-the-aacr Kentucky Health Wire en PressRelease 2026-04-22T20:05:00+00:00 BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026 https://ml.globenewswire.com/media/f5f2b913-06aa-4e1d-9368-55ff15fb3bd6/small/bbot-fullcolor-rgb-png.png https://www.kentuckyhealthwire.com/article/907389875-lb-pharmaceuticals-announces-publication-in-jama-psychiatry-of-results-from-phase-2-nova-1-trial-of-lb-102-in-schizophrenia Kentucky Health Wire en PressRelease 2026-04-22T20:05:00+00:00 LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia https://ml.globenewswire.com/media/90903161-520e-409f-b2ac-dd18677b4bb8/small/lb-pharma-logo-png.png https://www.kentuckyhealthwire.com/article/907391198-tomi-environmental-solutions-scales-automation-with-steramist-ihp-robot-upgrade-targets-fast-growing-robotaxi-market Kentucky Health Wire en PressRelease 2026-04-22T20:05:00+00:00 TOMI Environmental Solutions Scales Automation with SteraMist iHP Robot Upgrade; Targets Fast Growing Robotaxi Market https://ml.globenewswire.com/media/f8c7c513-0121-4507-84b7-3680626d9cf3/small/tomi-jpg.jpg https://www.kentuckyhealthwire.com/article/907390887-teknova-to-report-first-quarter-2026-financial-results-on-may-6-2026 Kentucky Health Wire en PressRelease 2026-04-22T20:01:00+00:00 Teknova to Report First Quarter 2026 Financial Results on May 6, 2026 https://ml.globenewswire.com/media/b4992253-8b06-4ba7-93c8-e1f9938c6556/small/updated-teknova-logo-2023-png.png https://www.kentuckyhealthwire.com/article/907389326-inventiva-strengthens-leadership-team-ahead-of-expected-phase-3-data-readout-of-lanifibranor Kentucky Health Wire en PressRelease 2026-04-22T20:00:00+00:00 Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor https://ml-eu.globenewswire.com/media/d96e203b-8941-46c7-888a-508900ab9a8b/small/logo-iva-jpg.jpg https://www.kentuckyhealthwire.com/article/907389620-transactions-in-zealand-pharma-shares-and-or-related-securities-by-persons-discharging-managerial-responsibilities-and-or-their-closely-associated Kentucky Health Wire en PressRelease 2026-04-22T20:00:00+00:00 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons https://ml-eu.globenewswire.com/media/31b5d115-c4a3-4dfd-b20e-d222199c4862/small/zealand-logo-1-png.png https://www.kentuckyhealthwire.com/article/907389682-inventiva-renforce-son-quipe-de-direction-l-approche-des-r-sultats-de-phase-3-du-lanifibranor Kentucky Health Wire en PressRelease 2026-04-22T20:00:00+00:00 Inventiva renforce son équipe de direction à l’approche des résultats de Phase 3 du lanifibranor https://ml-eu.globenewswire.com/media/d96e203b-8941-46c7-888a-508900ab9a8b/small/